Urea Cycle Disorders Treatment Market, by Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others (Low Protein Diet, Carglumic acid, etc.), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamy

Urea Cycle Disorders Treatment Market, by Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others (Low Protein Diet, Carglumic acid, etc.), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase, and NAGS – N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

The global urea cycle disorders treatment market includes various therapies such as amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, low protein diet, carglumic acid, etc. for the treatment of the inherited disorder such as urea cycle disorders, which affects various enzymes taking part in the urea cycle pathway in the human system. The urea cycle disorders are classified according to the deficiencies observed in different enzymes of the urea cycle such as OTC – ornithine transcarbamylase, ASD – argininosuccinic acid synthetase (citrullinemia), AG – Arginase, ALD – argininosuccinase acid lyase (argininosuccinic aciduria), CPS – carbamoyl phosphate synthetase, and NAGS – N-acetylglutamate synthetase.
Market Dynamics
Market players are focused on adopting different business strategies such as mergers and acquisitions in order to expand their offerings in the market.
For instance, in February 2017, Mead Johnson Nutrition Company (MJN) announced its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, added its globally-recognized brands, including Enfa and Nutramigen, which are used in dietary management of urea cycle disorder, to RB’s consumer health portfolio, thus strengthening its position globally.
Moreover, For Instance, In October 2017, Lucane Pharma SA was acquired by the Eurocept Pharmaceuticals, a company developing, distributing, and marketing of medicinal products in therapeutic areas such as anesthesia, oncology, immunology, and neurology. This acquisition has aided Eurocept Pharmaceuticals to invest in research and development of medicines for rare metabolic diseases such as urea cycle disorders.
Furthermore, Key players focused on inorganic strategies such as distribution agreements in order to strengthen their presence in the market.
For Instance, In 2016, Horizon Pharma plc and Swedish Orphan Biovitrum AB (publ) (Sobi), a biotechnological company in Sweden, announced the distribution agreement for the distribution of Ravicti in European countries including the U.K,. Germany, Italy, France, and Spain.
Key features of the study:
This report provides in-depth analysis of the global urea cycle disorders treatment market, provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
It profiles leading players in the global urea cycle disorders treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future market expansion and marketing tactics
The global urea cycle disorders treatment market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global urea cycle disorders treatment market
Detailed Segmentation:
Global Urea Cycle Disorders Treatment Market, By Treatment Type:
Amino Acid Supplements
Sodium Phenylbutyrate
Glycerol Phenylbutyrate
Sodium Benzoate
Others (Low Protein Diet, Carglumic acid, etc.)
Global Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type :
OTC – Ornithine Transcarbamylase
AS – Argininosuccinate Synthetase (citrullinemia)
AG – Arginase
AL – Argininosuccinate Lyase
CPS1 – Carbamoyl Phosphate Synthase
NAGS – N-acetylglutamate Synthase
Global Urea Cycle Disorders Treatment Market, By Route of Administration :
Oral
Injectable
Global Urea Cycle Disorders Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Urea Cycle Disorders Treatment Market, By Region:
North America
By Treatment Type:
Amino Acid Supplements
Sodium Phenylbutyrate
Glycerol Phenylbutyrate
Sodium Benzoate
Others (Low Protein Diet, Carglumic acid, etc.)
By Enzyme Deficiency Type:
OTC – Ornithine Transcarbamylase
AS – Argininosuccinate Synthetase (citrullinemia)
AG – Arginase
AL – Argininosuccinate Lyase
CPS1 – Carbamoyl Phosphate Synthase
NAGS – N-acetylglutamate Synthase
By Route of Administration :
Oral
Injecatble
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Treatment Type:
Amino Acid Supplements
Sodium Phenylbutyrate
Glycerol Phenylbutyrate
Sodium Benzoate
Others (Low Protein Diet, Carglumic acid, etc.)
By Enzyme Deficiency Type:
OTC – Ornithine Transcarbamylase
AS – Argininosuccinate Synthetase (citrullinemia)
AG – Arginase
AL – Argininosuccinate Lyase
CPS1 – Carbamoyl Phosphate Synthase
NAGS – N-acetylglutamate Synthase
By Route of Administration :
Oral
Injecatble
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type:
Amino Acid Supplements
Sodium Phenylbutyrate
Glycerol Phenylbutyrate
Sodium Benzoate
Others (Low Protein Diet, Carglumic acid, etc.)
By Enzyme Deficiency Type:
OTC – Ornithine Transcarbamylase
AS – Argininosuccinate Synthetase (citrullinemia)
AG – Arginase
AL – Argininosuccinate Lyase
CPS1 – Carbamoyl Phosphate Synthase
NAGS – N-acetylglutamate Synthase
By Route of Administration :
Oral
Injecatble
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type:
Amino Acid Supplements
Sodium Phenylbutyrate
Glycerol Phenylbutyrate
Sodium Benzoate
Others (Low Protein Diet, Carglumic acid, etc.)
By Enzyme Deficiency Type:
OTC – Ornithine Transcarbamylase
AS – Argininosuccinate Synthetase (citrullinemia)
AG – Arginase
AL – Argininosuccinate Lyase
CPS1 – Carbamoyl Phosphate Synthase
NAGS – N-acetylglutamate Synthase
By Route of Administration :
Oral
Injecatble
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment Type:
Amino Acid Supplements
Sodium Phenylbutyrate
Glycerol Phenylbutyrate
Sodium Benzoate
Others (Low Protein Diet, Carglumic acid, etc.)
By Enzyme Deficiency Type:
OTC – Ornithine Transcarbamylase
AS – Argininosuccinate Synthetase (citrullinemia)
AG – Arginase
AL – Argininosuccinate Lyase
CPS1 – Carbamoyl Phosphate Synthase
NAGS – N-acetylglutamate Synthase
By Route of Administration :
Oral
Injecatble
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Treatment Type:
Amino Acid Supplements
Sodium Phenylbutyrate
Glycerol Phenylbutyrate
Sodium Benzoate
Others (Low Protein Diet, Carglumic acid, etc.)
By Enzyme Deficiency Type:
OTC – Ornithine Transcarbamylase
AS – Argininosuccinate Synthetase (citrullinemia)
AG – Arginase
AL – Argininosuccinate Lyase
CPS1 – Carbamoyl Phosphate Synthase
NAGS – N-acetylglutamate Synthase
By Route of Administration :
Oral
Injecatble
By Distribution Channel :
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Bausch Health Companies, Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Recordati Rare Diseases Inc.
Lucane Pharma SA
Acer Therapeutics
Ultragenyx Pharmaceutical Inc.
Aeglea BioTherapeutics
Arcturus Therapeutics Holdings Inc.
Orpharma Pty Ltd.
Selecta Biosciences, Inc.
Abbott Laboratories
NESTLÉ S.A.
DANONE S.A.
Mead Johnson & Company, LLC
“*” marked represents similar segmentation in other categories in the respective section.